The aetiology of benign prostatic hyperplasia (BPH) remains unclear. The objective of the present study was to test the insulin, oestradiol and metabolic syndrome hypotheses as promoters of BPH. The design was a risk factor analysis of BPH in which the total prostate gland volume was related to endocrine and anthropometric factors. The participants studied were 184 representative men, aged 72-76 years, residing in Gö teborg, Sweden. Using a multivariate analysis, BPH as measured by the total prostate gland volume correlated statistically significantly with fasting serum insulin (b ¼ 0.200, P ¼ 0.028), free oestradiol (b ¼ 0.233, P ¼ 0.008) and lean body mass (b ¼ 0.257, P ¼ 0.034). Insulin and free oestradiol appear to be independent risk factors for BPH, confirming both the insulin and the oestradiol hypotheses. Our findings also seem to confirm the metabolic syndrome hypothesis. The metabolic syndrome and its major endocrine aberration, hyperinsulinaemia, are possible primary events in BPH.
Introduction
The aetiology of benign prostatic hyperplasia (BPH) is unknown, although this disorder is the most common benign neoplasm in men. 1, 2 In the past, most interest has been focused on the steroid hormones, especially testosterone and oestradiol and their metabolites as promoters of BPH. 2, 3 The majority of studies have failed to show an association between androgen levels and the prostate gland volume. However, many reports have shown a link between oestradiol, or the quotient between oestradiol and testosterone on the one hand, and BPH as measured by the total prostate gland volume on the other. 2, 4, 5 All these findings suggest that oestradiol is a promoter of BPH. We are referring to this notion as 'the oestradiol hypothesis'.
In recent years, attention has been more and more focused on the metabolic syndrome and its major endocrine aberration-hyperinsulinaemia. [6] [7] [8] [9] [10] [11] [12] Our group started its research prompted by the clinical observation that diabetic and/or obese men seem to have a larger prostate gland than men without these disorders. In our reports, 11 out of 11 components of the metabolic syndrome were linked to fast-growing BPH. This indicates that BPH also is a component of the metabolic syndrome. We are referring to this as 'the metabolic syndrome hypothesis'.
The major endocrine aberration in connection with the metabolic syndrome is hyperinsulinaemia. 13 It seemed biologically plausible that insulin is the link between the metabolic syndrome and BPH. This relationship has been confirmed in all our previous studies using univariate statistics. [6] [7] [8] [9] Moreover, multivariate statistics showed that fasting serum insulin was an independent risk factor for BPH. All these findings suggest that insulin is a promoter of BPH. Other authors have reached the same conclusion. 10, 11, 14 We refer to this as 'the insulin hypothesis'. Thus, there seems to be a link between oestradiol, the metabolic syndrome, and insulin on the one hand, and BPH on the other. In the present report, these three hypotheses will be tested once again on a representative group of men, aged 72-76 years, living in Gö teborg, Sweden.
Methods

Participants
The Mr OS Study is a multicentre study on a representative group of elderly men (age 69-80 years) in Sweden (n ¼ 3014), Hong Kong (n ¼ E2000) and the United States (n ¼ E6000). This investigation is an international study of osteoporosis in men that deals with clinical, anthropometric, metabolic, endocrine and genetic factors. The men in Sweden were randomly selected using national population registers and were contacted and asked to participate in the study. 15 To be eligible for participation the men had to be able to walk without aids and were not allowed to have a bilateral hip prosthesis. There were no other exclusion criteria.
In this report, a subgroup of the Mr OS Study participants involving men living in Gö teborg, Sweden, were examined with respect to the association between endocrine and anthropometric factors on the one hand and BPH as measured by the prostate gland volume, on the other. This subgroup included 184 men, 72-76 years of age. Men previously diagnosed with prostate cancer or subjected to treatment due to BPH were excluded, after which 159 men remained to be evaluated. Pertinent participant data are given in Table 1 . The Mr OS Study in Sweden was approved by the ethics committee of Gö teborg University. Informed consent was obtained from all study participants.
Assessment of anthropometric variables
Height and weight were measured using standard equipment. Two consecutive measurements of height were performed in the same session and the average of these measurements was calculated. If there was a discrepancy of X5 mm between the first two measurements, a third measurement was performed and the average of the two values with the least mutual discrepancy was calculated. Lean body mass and fat mass were assessed using the DXA Hologic QDR 4500/ A-Delphi (Hologic). Pertinent median anthropometric variables are given in Table 1 .
Assessment of sex hormones and fasting insulin
All serum samples were collected at 0800 hours in the morning after at least 10 h of fasting and non-smoking.
Serum insulin samples were transported directly to the laboratory. Serum samples for sex hormones were stored at À80 1C.
Total oestradiol (E2) was measured using an ultrasensitive radioimmunoassay (RIA; Orion Diagnostics, Esboo, Finland; limit detection 5 pM (140 pg per 100 ml), intra-assay CV 3% and inter-assay CV 6%). Total testosterone (T) was measured using RIA (Orion Diagnostics; limit detection 0.1 nM (3 ng per 100 ml), intra-assay CV 6% and inter-assay CV 6%). Sex hormonebinding globuline (SHBG) was measured using immunoradiometric assay (Orion Diagnostics; limit of detection 1.3 nM, intra-assay CV 3% and inter-assay CV 7%). Two subjects had undetectable E2 levels and one had undetectable T levels.
Free testosterone (FT) and free oestradiol (FE2) were calculated in accordance with the method described by Vermeulen et al. 16 and Van den Beld et al., 17 taking the concentrations of total T, total E2 and SHBG into account and assuming a fixed albumin concentration of 43 g l À1 . All samples were analysed in duplicate in one laboratory and the duplicates were averaged for further analyses.
Serum insulin was measured using an immunometric method based on chemiluminescense technology on an ADIVA Centaur (Bayer AB, Gothenburg, Sweden) with a detection limit of 0.1 mU ml À1 and intra-and inter-assay CV below 10%.
Assessment of the prostate gland volume
The prostate gland was examined using digital rectal examination and ultrasound equipment (B-K Medical Panther 2002 ADI). The prostate gland volume was determined by means of ultrasound using the ellipsoid method.
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Statistical analysis
Univariate associations among variables were examined using Pearson's correlation after log transformations of markedly non-normally distributed variables (Tables 2  and 3 ). The independent predictors of the prostate gland volume were tested using linear regression analyses including height, serum insulin, total body fat mass, total body lean mass, FT and free oestradiol (Table 4) .
Results
Pertinent data on the study participants are given in Table 1 . The mean prostate gland volume was 47 ml (13-139 ml). Endocrine factors and benign prostatic hyperplasia J Hammarsten et al
The following endocrine variables suggested to be established components of the metabolic syndrome were positively correlated to BPH: fasting serum insulin and free oestradiol. The quotient testosterone/oestradiol and SHBG was negatively correlated to BPH as measured by the prostate gland volume. Total oestradiol and total FT did not reach statistical significance ( Table 2) .
The following anthropometric variables suggested to be components of the metabolic syndrome were linked to BPH as measured by the prostate gland volume: body mass index (BMI), body weight and lean body mass. Fat body mass did not reach statistical significance in this relationship (Table 3) .
Using multivariate analysis, fasting serum insulin, free oestradiol and lean body mass were linked to BPH (Table 4) .
Discussion
The most important findings in the present report are that both insulin and free oestradiol were independent risk factors for BPH, suggesting that these hormones are promoters of BPH. Another important finding was that BPH is linked to several established endocrine and anthropometric components of the metabolic syndrome. This suggests that BPH is a component of the metabolic syndrome.
In the present report, insulin was found to be an independent risk factor for BPH as measured by the prostate gland volume. Insulin has also been shown previously to be a risk factor for BPH. [6] [7] [8] [9] [10] [11] 14 All these data support the hypothesis that insulin is a promoter of BPH. Insulin resistance may change the risk of BPH through several biological pathways. The most obvious pathway is by the insulin itself, as shown in the present report. Insulin is a mitogen and a growth factor for prostate epithelial cells and also has an anti-apoptotic effect. 20 Moreover, hyperinsulinaemia stimulates the liver to produce more insulin-like growth factor 1 (IGF-1), another mitogen and an anti-apoptotic agent. 20 Serum IGF-1 has been associated with BPH in several studies, 21, 22 but not in all. 23 Although stimulating liver production of IGF-1, insulin also suppresses the production of IGFBP-1 of the liver, which might result in an even higher increase of the free biologically active IGF-1 level. 20 Insulin resistance may also change the risk of BPH through the obesity-sex hormone pathway. 24 Insulin resistance generates obesity and with increasing fatty tissue accumulation, there is an increase in aromatase activity, associated with a greater conversion of testosterone to oestradiol in men. This, in turn, increases the oestradiol level and reduces the testosterone/oestradiol quotient as shown in the present report.
There are both clinical and experimental data linking oestradiol to BPH. 2, 4, 5 However, in many of these clinical reports, poor surrogate measurements of BPH have been used. In the present report, the free oestradiol level was shown to be independently linked to the total prostate gland volume, which has been shown to correlate highly significantly with the transition zone volume. 8 The transition zone is the exclusive site of the origin of BPH. 25 All these data taken together support the hypothesis that free oestradiol is a promoter of BPH. However, some data are inconsistent with the oestradiol hypothesis. In a report on the effect of stilbestrol therapy on the size of the benignly hypertrophied prostate gland, it was found that the size of the prostate gland was reduced in 10 of 13 cases. 26 Thus, as early as in the 40s, researchers summarized that a relatively slight excess of oestrogenic hormone produces an indirect 'castration effect' on the secondary sex organs. This was largely due to inhibition of the pituitary gonadotropic hormone and subsequent testicular atrophy. 27 Other evidence that is inconsistent with the oestradiol hypothesis are the reports that treatment with aromatase inhibitors with observed reductions of the oestradiol level has no effect on clinically established BPH. 28, 29 In the present report, 8 out of 10 established endocrine and anthropometric components of the metabolic syndrome were linked to BPH. In previous reports, 11 out of 11 established components of the metabolic syndrome were linked to BPH (Table 5) . Thus, 19 out of 21 established components of the metabolic syndrome have been shown to be risk factors for BPH in these reports. However, the strongest evidence in the present report in support of the hypothesis that BPH is a component of the metabolic syndrome is the fact that BPH and components of the metabolic syndrome share the same endocrine and anthropometric aberrations.
When it comes to endocrine factors, the following are linked to components of the metabolic syndrome: hyperinsulinaemia, 13 an increased level of oestradiol, 30 a reduced level of testosterone, 31,32 a reduced testosterone/oestradiol quotient 33 and a reduced level of SHBG. 34 All these endocrine aberrations, with the exception of a reduced testosterone level, which did not reach statistical significance, were linked to BPH as measured by the total prostate gland volume in the present report. It may be questioned why an inverse testosterone level did not come out as a predictor of BPH in the present report, as a reduced testosterone level has been linked to the metabolic syndrome in several reports. 31, 32 Speculatively, the prostate gland tissue is a testosterone-dependent organ and, consequently, when the testosterone level decreases as a result from an increasingly pronounced metabolic syndrome, the b-Coefficients are given after adjustment for the following variables in the model: height, serum insulin, total body fat mass, total body lean mass, free testosterone and free oestradiol.
Endocrine factors and benign prostatic hyperplasia J Hammarsten et al growth-stimulating effect on the prostate gland by other aberrations might possibly be reduced.
As for anthropometric factors, lean mass was found to be an independent risk factor for BPH. In two reports, lean mass has been shown to be related to the metabolic syndrome in women, 35, 36 but has not been shown in men. On the other hand, another well-known anthropometric component of the metabolic syndrome, that is obesity, as measured by fat mass, did not come out significantly as a risk factor for BPH. In contrast to this, two other expressions of obesity, that is body weight and BMI, were related to BPH. The reason for this contradictory outcome could be that BPH-as most components of the metabolic syndrome-is primarily linked to visceral obesity rather than to the overall obesity. 7, 14, 37 In the clinical setting, waist measurement is probably a better risk factor for BPH than BMI.
To sum up, 19 out of 21 established components of the metabolic syndrome turned out to be risk factors for BPH in our reports (Table 5) . Reduced testosterone level and increased fat body mass were not shown to be predictors of BPH, but there are understandable causes for this outcome. Hence, all our data indicate that BPH is a new component of the metabolic syndrome. If this is true, BPH might be another Western civilization disorder in addition to type II diabetes, atherosclerosis, hypertension, obesity and dyslipidaemia.
The classic metabolic syndrome in men has been defined in different ways by several health organizations. 38 The practical use of the composite definitions of the metabolic syndrome focuses on its potential value as a risk factor for the development of cardiovascular diseases. However, it has been recently claimed that the classic metabolic syndrome is imprecisely defined and appears to be of limited independent value as a marker of risk for cardiovascular diseases. 38 Given these limitations of the classic metabolic syndrome, it is reasonable not to use composite definitions of the metabolic syndrome in BPH research. In the present report, none of these established definitions have been used. In clinical practice, single or multiple components of the metabolic syndrome associated with BPH in our reports may be looked upon as alert signs for BPH. Thus, in the clinical setting, the results of our reports indicate that any physician confronted by a patient with type II diabetes, hypertension, visceral obesity and dyslipidaemia or some other component of the metabolic syndrome associated with BPH should consider the possibility that the patient also has lower urinary tract symptoms due to BPH. Conversely, a physician who is confronted by a patient with lower urinary tract symptoms due to BPH should consider the possibility that the patient also may have any of the above-mentioned conditions.
In the past, many different definitions of BPH have been used. Most definitions have been based on the Hald's concept, which combines prostate volume, lower urinary tract symptoms and objective proof of difficult micturition. 39 These definitions seem to be inadequate tools when it comes to exploring aetiological factors in BPH. More recently, BPH has been defined as a noncancerous enlargement of the prostate gland focusing on the fact that BPH constitutes a benign tumour of the prostate gland. 40 It has been recently concluded that the prostate gland volume is an objective, quantitative measure of BPH. 41 Thus, the total prostate gland volume, used as a surrogate measure of BPH in the present study, seems to be an adequate measure of BPH.
It may be argued that the associations in the present report between BPH on the one hand, and endocrine and anthropometric factors on the other, are largely confirmatory. However, previous studies have involved clinical studies including men referred because of lower urinary tract symptoms. In the present report, the same associations have been confirmed for the first time in a group of men representative for a whole population. It may also be argued that the associations are modest, although statistically significant. However, it must be kept in mind that the prostate gland volume, used as a proxy of BPH in the present report, is the result of a process going on for more than 30 years, whereas many of the endocrine and anthropometric measurements are highly volatile variables one morning at the end of this period of time.
On the basis of the present report and other current knowledge, the following hypothesis on the pathogenesis of BPH is suggested. As a consequence of unhealthy lifestyle factors, including poor diet, low physical activity, obesity and genetic factors, a defective insulinstimulated glucose uptake, that is insulin resistance, is generated, mostly in the muscle tissue. To compensate for this defective insulin-stimulated glucose uptake, secondary hyperinsulinaemia is generated to maintain the glucose homoeostasis as shown in the present report. Hyperinsulinaemia, in turn, stimulates the liver which results in an increase of the free biologically active IGF-1 level. 20 As another consequence of constant hyperinsulinaemia, a cluster of disorders, including visceral obesity, is generated over the years. One consequence of obesity is an increased aromatase activity that results in an increased oestradiol level and a decreased testosterone/oestradiol balance, as shown in the present report. However, as mentioned above, other reports disqualify oestradiol as a promoter of BPH. Thus, this new hypothesis on the pathogenesis of BPH states that an increased insulin and IGF-1 level increase the prostate gland volume. The hypothesis also states that the metabolic syndrome and its major endocrine aberration, Table 5 Compilation of established components of the metabolic syndrome, which have been shown to be risk factors for BPH in the present and our previous reports Fasting serum insulin (present report [6] [7] [8] [9] ) Free oestradiol (present report)hyperinsulinaemia, are primary events for BPH. This hypothesis will be tested in a prospective study now in progress.
In summary, insulin and free oestradiol appear to be independent risk factors for BPH, confirming both the insulin and the oestradiol hypothesis. Our findings also seem to confirm the metabolic syndrome hypothesis stating that BPH is a new component of the metabolic syndrome. The metabolic syndrome and its major endocrine aberration, hyperinsulinaemia, are possible primary events for BPH.
